

# OUR FOOTPRINT – MPP'S OVERALL IMPACT IN 10 YEARS OF OPERATIONS



**18.55**  
billion doses

of treatments supplied through  
MPP's licences

**10**

patent holders

signed agreements with MPP

**18**

products

licensed to MPP



**23**

generic  
manufacturers  
and  
product  
developers

sublicensed from MPP

**155**

active product development  
projects

MPP licences have generated  
**USD 1.96 billion**

in global health savings  
through the procurement of  
more affordable quality-assured  
medicines from MPP generic  
partners through  
an average price reduction



**of 81%**

relative to the originator price

Generic products facilitated  
by MPP have been distributed in

**148 countries**

providing

**49.71 million  
patient-years of  
treatment**

from January 2012 to  
December 2020

*MPP's impact is calculated and  
verified by KPMG*

# 2020 AT-A-GLANCE

## JANUARY

- The University of Liverpool and the University of Washington secure Unitaid grants for long-acting products; MPP proudly partners with both to increase access to these revolutionary technologies

## FEBRUARY

- MPP co-sponsors a conference on long-acting injectables and implantables with MedinCell
- MPP and Viartis (through its subsidiary Mylan) sign an agreement to scale up access to the first generic version of hepatitis C treatment glecaprevir/pibrentasvir
- At WHO's request, MPP begins to collect patent data on treatments being tested for COVID-19 and adds these to MedsPaL

## MARCH

- Affordable versions of hepatitis C medicine daclatasvir from Bristol-Myers Squibb become available in additional countries
- MPP's Board temporarily expands MPP's mandate to include any health technology that could contribute to the global response to COVID-19

## APRIL

- MedinCell secures Unitaid grant for long-acting solution for malaria; MPP will partner on accelerating access

## MAY

- MPP strongly supports multilateral COVID-19 global response and stands ready to contribute to the Access to COVID-19 Tools Accelerator (ACT-A)
- MPP's statement at the 73rd World Health Assembly welcomes Resolution WHA73.1 that calls to work collaboratively through "existing mechanisms for voluntary pooling and licensing of patents"

## JUNE

- Marking its 10th anniversary, MPP launches its new website
- Leading up to AIDS 2020 (virtual) conference, MPP organises an online roundtable on scaling up access to antiretroviral therapy

## JULY

- MPP is a co-publisher, along with WHO and seven other leading organisations, of the policy brief 'Considerations for introducing new antiretroviral drug formulations for children'
- MPP co-organises a satellite symposium at AIDS 2020 (virtual) together with Unitaid and WHO. The panel discusses access to long-acting technologies for HIV in LMICs

## AUGUST

- MPP and the International Diabetes Federation join forces to improve access to diabetes medicines

## SEPTEMBER

- Dr Jinliang Li joins MPP's Governance Board
- On World Heart Day, MPP and the World Heart Federation sign MoU to improve access to affordable cardiovascular disease medicines

## OCTOBER

- MPP co-organises a panel at the World Health Summit 2020 (virtual) with Unitaid and WHO; discussion focuses on access to essential medicines in LMICs – a prerequisite to achieving Universal Health Coverage
- Algeria gains inclusion to ViiV Healthcare/MPP adult licence enabling greater access to dolutegravir-based HIV treatments
- MPP showcases the progress and good initiatives taken in Kenya for greater access to medicines through a series of videos and written pieces

## NOVEMBER

- MPP leads an open pledge bringing together generic manufacturers to combine forces for developing and delivering affordable COVID-19 interventions
- MPP participates in the Vatican meeting; keeps "access to child-friendly medicines" high on the agenda
- MPP secures a new USD 34.3 million grant from Unitaid for five years (2021-2025)
- ViiV Healthcare and MPP expand access to dolutegravir-based regimens for people living with HIV in Azerbaijan, Belarus, Kazakhstan and Malaysia with an innovative new licensing agreement

## DECEMBER

- Prof. Mojisola Christianah Adeyeye and Prof. John-Arne Røttingen join MPP's Governance Board
- MPP sublicenses sutezolid, an investigational drug for TB treatment, to the Gates Medical Research Institute, paving the way for clinical development
- WIPO joins MPP's Governance Board as a non-voting member



# 10 YEARS, 10 LESSONS

Since 2010, and the foundation of MPP, much has happened – dozens of negotiations on public health licences, hundreds of partnerships across sectors, billions of doses of treatment supplied through MPP's licences, and much more. And behind all these successes are hard-earned lessons that we have gathered, one lesson at a time. Each of these 10 precious lessons, as reflected in our partners' voices, has made our foundation stronger than ever.



## TURNING IMPOSSIBLE INTO **POSSIBLE**

Ten years on, the model has proved its worth. Since its creation in 2010, MPP's 'pooled' intellectual property has led to the supply of nearly 19 billion doses of medicines across 148 countries and saved USD 1.96 billion in public health spending. The value of MPP's work is recognised by the global health community and corporations alike.

– ELLEN 't HOEN, Director, Medicines Law & Policy; founder and MPP's first Executive Director



## **SPEED** – WHEN LIVES ARE AT STAKE, SPEED IS CRITICAL

Mylan first signed a MPP sublicense for a direct-acting antiviral called daclatasvir in October 2016, following approval of the BMS version of the product by the US Food and Drug Administration (USFDA) in 2015. In May 2019, Mylan received WHO Prequalification (PQ) for the product. Mylan's PQ represents one of the fastest speeds by which any treatment, for any disease, has gone from initial branded approval to the first quality-assured generic – in less than four years.

– ANIL SONI, former Head of Global Infectious Diseases, Viatris (through its subsidiary Mylan)



## **AFFORDABILITY** – EVERY CENT COUNTS

In South Africa, we have had very high prices, particularly in antiretroviral medicines. In 2010, the annual cost of first-line treatment was USD 250, while second-line treatments cost as much as USD 850. In June 2020, thanks to tremendous efforts from partners including MPP, the fixed-dose combination with dolutegravir is just USD 4.33 a month.

– PRECIOUS MATSOSO, Former Director-General, National Department of Health, South Africa



## **ACCESSIBILITY** – COMBATting EPIDEMICS BY INCREASING ACCESS TO MEDICINES

Broad access to WHO-prioritised medicines is critical to ending HIV/AIDS, so enabling the wide availability of dolutegravir to people living with HIV – regardless of their income or where they live – has been central to ViiV Healthcare's access to medicines strategy and our work with MPP since 2014.

– DEBORAH WATERHOUSE, Chief Executive Officer, ViiV Healthcare



## **AVAILABILITY** – THE CRITICAL NEED FOR PARTNERSHIPS

WHO Global TB Programme commends the achievements of MPP in the last decade and looks forward to seeing further expansion of the MPP model to include more medicines with high public health value in TB, leading to increased access, global availability and affordable pricing in places where they are needed the most – in low- and middle-income countries.

– The Global TB Programme, WORLD HEALTH ORGANIZATION (WHO)



## **INCLUSIVITY** – A SLOW AND STEADY UPWARD BATTLE THAT CONTINUES

My wish for the future is to see better-designed clinical trials (for TB) and greater civil society participation in the design. I hope that the next 10 years will bring us head-to-head comparisons between treatments so that we can see clearly how effective each component of the regimen is, and all vulnerable populations, including children, pregnant women and people living with HIV, can get the best combinations they deserve.

– WIM VANDELDE, GNP+, Global TB Community Advisory Board



## **EQUITY** – TOWARDS A FAIRER SOCIETY

There is no reason why people living in the North have a different treatment to those living in the South. It is because of the work of organisations like MPP and Unitaid that DTG is widely available in Kenya today. MPP accelerates the availability of generic versions and makes treatments affordable for countries like mine and for them to be scaled up to even the most remote villages.

– NELSON OTWOMA, Chief Executive Officer, NEPHAK



## **SUSTAINABILITY** – PERFECTING A MECHANISM THAT LASTS

The voluntary licensing mechanism and the partnership is a highly symbiotic one – with MPP achieving a sustainable supply of affordable, high-quality medicines for those in need and generic companies getting access to products and markets that would otherwise be impossible without licences. It is a win-win model, and it is a fundamentally sustainable model. So licensing is here to stay.

– UMESH K, Senior Vice President, Global Antivirals, Aurobindo



## **TRANSPARENCY** – SETTING A GOLD STANDARD

Since 2012, MPP has become the main driving force behind voluntary licensing in the pharmaceutical industry. MPP prioritises transparent and access-friendly terms in licences that support rapid access to key products in large numbers of countries where the biggest disease burden lies.

– JAYASREE K. IYER, Executive Director, Access to Medicine Foundation



## **INNOVATION** – PUSHING LIMITS IN PAEDIATRIC MEDICINES

EGPAF is proud of its collaboration with MPP, an organisation that will continue working until every child and young person has the quality medicines they need to live a happy, healthy life. MPP understands that innovation is vital to achieving this goal. Improved (paediatric) formulations bring hope to families who thought they might never find the solutions they need not just to survive, but thrive.

– CHIP LYONS, CEO and President, Elizabeth Glaser Pediatric AIDS Foundation (EGPAF)